It is noteworthy that semaglutide has no proven direct biological effect on the liver, as glucagon-like peptide-1 (GLP-1) receptors are not expressed in hepatic tissue (Protein Atlas, [15]
Independent analytical laboratories test the actual product and report results with no financial incentive to inflate quality claims
In January 2026, the MHRA approved a higher 7.2mg maximum weekly dose, followed by the introduction of a single-dose 7.2mg Wegovy pen in April 2026
Common benefits of peptide therapy include increased muscle mass and strength, boosted energy and metabolism, weight loss, better sleep, faster healing, cognitive enhancement, improved skin health, anti-aging effects, and immune support
Mounjaro is the only GLP-1 receptor agonist licensed in the UK that has been shown to reduce the absorption of oral contraceptives